BACKGROUND: External validation of risk models is critical for risk-stratified breast cancer prevention. We used the Individualized Coherent Absolute Risk Estimation (iCARE) as a flexible tool for risk model development and comparative model validation and to make projections for population risk stratification. METHODS: Performance of two recently developed models, one based on the Breast and Prostate Cancer Cohort Consortium analysis (iCARE-BPC3) and another based on a literature review (iCARE-Lit), were compared with two established models (Breast Cancer Risk Assessment Tool and International Breast Cancer Intervention Study Model) based on classical risk factors in a UK-based cohort of 64 874 white non-Hispanic women (863 patients) age 35-74 years. Risk projections in a target population of US white non-Hispanic women age 50-70 years assessed potential improvements in risk stratification by adding mammographic breast density (MD) and polygenic risk score (PRS). RESULTS: The best calibrated models were iCARE-Lit (expected to observed number of cases [E/O] = 0.98, 95% confidence interval [CI] = 0.87 to 1.11) for women younger than 50 years, and iCARE-BPC3 (E/O = 1.00, 95% CI = 0.93 to 1.09) for women 50 years or older. Risk projections using iCARE-BPC3 indicated classical risk factors can identify approximately 500 000 women at moderate to high risk (>3% 5-year risk) in the target population. Addition of MD and a 313-variant PRS is expected to increase this number to approximately 3.5 million women, and among them, approximately 153 000 are expected to develop invasive breast cancer within 5 years. CONCLUSIONS: iCARE models based on classical risk factors perform similarly to or better than BCRAT or IBIS in white non-Hispanic women. Addition of MD and PRS can lead to substantial improvements in risk stratification. However, these integrated models require independent prospective validation before broad clinical applications. Published by Oxford University Press 2019. This work is written by US Government employees and is in the public domain in the US.
BACKGROUND: External validation of risk models is critical for risk-stratified breast cancer prevention. We used the Individualized Coherent Absolute Risk Estimation (iCARE) as a flexible tool for risk model development and comparative model validation and to make projections for population risk stratification. METHODS: Performance of two recently developed models, one based on the Breast and Prostate Cancer Cohort Consortium analysis (iCARE-BPC3) and another based on a literature review (iCARE-Lit), were compared with two established models (Breast Cancer Risk Assessment Tool and International Breast Cancer Intervention Study Model) based on classical risk factors in a UK-based cohort of 64 874 white non-Hispanic women (863 patients) age 35-74 years. Risk projections in a target population of US white non-Hispanic women age 50-70 years assessed potential improvements in risk stratification by adding mammographic breast density (MD) and polygenic risk score (PRS). RESULTS: The best calibrated models were iCARE-Lit (expected to observed number of cases [E/O] = 0.98, 95% confidence interval [CI] = 0.87 to 1.11) for women younger than 50 years, and iCARE-BPC3 (E/O = 1.00, 95% CI = 0.93 to 1.09) for women 50 years or older. Risk projections using iCARE-BPC3 indicated classical risk factors can identify approximately 500 000 women at moderate to high risk (>3% 5-year risk) in the target population. Addition of MD and a 313-variant PRS is expected to increase this number to approximately 3.5 million women, and among them, approximately 153 000 are expected to develop invasive breast cancer within 5 years. CONCLUSIONS: iCARE models based on classical risk factors perform similarly to or better than BCRAT or IBIS in white non-Hispanic women. Addition of MD and PRS can lead to substantial improvements in risk stratification. However, these integrated models require independent prospective validation before broad clinical applications. Published by Oxford University Press 2019. This work is written by US Government employees and is in the public domain in the US.
Authors: Anne Marie McCarthy; Zoe Guan; Michaela Welch; Molly E Griffin; Dorothy A Sippo; Zhengyi Deng; Suzanne B Coopey; Ahmet Acar; Alan Semine; Giovanni Parmigiani; Danielle Braun; Kevin S Hughes Journal: J Natl Cancer Inst Date: 2020-05-01 Impact factor: 13.506
Authors: Constance D Lehman; Sarah Mercaldo; Leslie R Lamb; Tari A King; Leif W Ellisen; Michelle Specht; Rulla M Tamimi Journal: J Natl Cancer Inst Date: 2022-10-06 Impact factor: 11.816
Authors: Anushri Chitkara; Ines Mesa-Eguiagaray; Sarah H Wild; Peter S Hall; David A Cameron; Andrew H Sims; Jonine D Figueroa Journal: Breast Cancer Res Treat Date: 2022-09-18 Impact factor: 4.624
Authors: Zhaohui Du; Guimin Gao; Babatunde Adedokun; Thomas Ahearn; Kathryn L Lunetta; Gary Zirpoli; Melissa A Troester; Edward A Ruiz-Narváez; Stephen A Haddad; Parichoy PalChoudhury; Jonine Figueroa; Esther M John; Leslie Bernstein; Wei Zheng; Jennifer J Hu; Regina G Ziegler; Sarah Nyante; Elisa V Bandera; Sue A Ingles; Nicholas Mancuso; Michael F Press; Sandra L Deming; Jorge L Rodriguez-Gil; Song Yao; Temidayo O Ogundiran; Oladosu Ojengbe; Manjeet K Bolla; Joe Dennis; Alison M Dunning; Douglas F Easton; Kyriaki Michailidou; Paul D P Pharoah; Dale P Sandler; Jack A Taylor; Qin Wang; Clarice R Weinberg; Cari M Kitahara; William Blot; Katherine L Nathanson; Anselm Hennis; Barbara Nemesure; Stefan Ambs; Lara E Sucheston-Campbell; Jeannette T Bensen; Stephen J Chanock; Andrew F Olshan; Christine B Ambrosone; Olufunmilayo I Olopade; Joel Yarney; Baffour Awuah; Beatrice Wiafe-Addai; David V Conti; Julie R Palmer; Montserrat Garcia-Closas; Dezheng Huo; Christopher A Haiman Journal: J Natl Cancer Inst Date: 2021-09-04 Impact factor: 11.816
Authors: Chi Gao; Eric C Polley; Steven N Hart; Hongyan Huang; Chunling Hu; Rohan Gnanaolivu; Jenna Lilyquist; Nicholas J Boddicker; Jie Na; Christine B Ambrosone; Paul L Auer; Leslie Bernstein; Elizabeth S Burnside; A Heather Eliassen; Mia M Gaudet; Christopher Haiman; David J Hunter; Eric J Jacobs; Esther M John; Sara Lindström; Huiyan Ma; Susan L Neuhausen; Polly A Newcomb; Katie M O'Brien; Janet E Olson; Irene M Ong; Alpa V Patel; Julie R Palmer; Dale P Sandler; Rulla Tamimi; Jack A Taylor; Lauren R Teras; Amy Trentham-Dietz; Celine M Vachon; Clarice R Weinberg; Song Yao; Jeffrey N Weitzel; David E Goldgar; Susan M Domchek; Katherine L Nathanson; Fergus J Couch; Peter Kraft Journal: J Clin Oncol Date: 2021-06-08 Impact factor: 50.717
Authors: Anne S Quante; Anika Hüsing; Jenny Chang-Claude; Marion Kiechle; Rudolf Kaaks; Ruth M Pfeiffer Journal: Cancer Prev Res (Phila) Date: 2021-03-05